EMA Authorised: Abilify Maintena (aripiprazole) — Otsuka Pharmaceutical Netherlands B.V.

View source ↗

Summary

The European Medicines Agency authorised Abilify Maintena (aripiprazole) with Otsuka Pharmaceutical Netherlands B.V. as the marketing authorization holder, for …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizophrenia

Drugs mentioned

• ABILIFY MAINTENA (ARIPIPRAZOLE)

Snippet

Status: Authorised. Therapeutic area: Schizophrenia. MAH: Otsuka Pharmaceutical Netherlands B.V.. Decision date: 27/10/2025